SG10201913696YA - Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer - Google Patents
Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancerInfo
- Publication number
- SG10201913696YA SG10201913696YA SG10201913696YA SG10201913696YA SG10201913696YA SG 10201913696Y A SG10201913696Y A SG 10201913696YA SG 10201913696Y A SG10201913696Y A SG 10201913696YA SG 10201913696Y A SG10201913696Y A SG 10201913696YA SG 10201913696Y A SG10201913696Y A SG 10201913696YA
- Authority
- SG
- Singapore
- Prior art keywords
- listeria
- antagonist
- combination
- prostate cancer
- based vaccine
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title 1
- 229940124060 PD-1 antagonist Drugs 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462026221P | 2014-07-18 | 2014-07-18 | |
US201462039011P | 2014-08-19 | 2014-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913696YA true SG10201913696YA (en) | 2020-03-30 |
Family
ID=55079087
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701149SA SG11201701149SA (en) | 2014-07-18 | 2015-07-17 | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
SG10201913696YA SG10201913696YA (en) | 2014-07-18 | 2015-07-17 | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701149SA SG11201701149SA (en) | 2014-07-18 | 2015-07-17 | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
Country Status (11)
Country | Link |
---|---|
US (2) | US9907849B2 (en) |
EP (1) | EP3193921A4 (en) |
KR (1) | KR20170052569A (en) |
CN (2) | CN106999561A (en) |
AU (1) | AU2015289533B2 (en) |
CA (1) | CA2955612C (en) |
IL (1) | IL250187B (en) |
MA (1) | MA40344A (en) |
MX (1) | MX2017000857A (en) |
SG (2) | SG11201701149SA (en) |
WO (1) | WO2016011357A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
DK2170959T3 (en) * | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
CA2829960A1 (en) | 2011-03-11 | 2012-09-20 | John Rothman | Listeria-based adjuvants |
WO2013138337A1 (en) | 2012-03-12 | 2013-09-19 | Advaxis | Suppressor cell function inhibition following listeria vaccine treatment |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
EA035037B1 (en) | 2013-12-12 | 2020-04-21 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
CN106456726A (en) | 2014-02-18 | 2017-02-22 | 阿德瓦希斯公司 | Biomarker directed multi-target immunotherapy |
SG10202011841WA (en) | 2014-04-24 | 2021-01-28 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
MA41644A (en) | 2015-03-03 | 2018-01-09 | Advaxis Inc | LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF |
MX2017011644A (en) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof. |
JP2018514550A (en) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Treatment of PD-L1 negative melanoma using anti-PD-1 antibody and anti-CTLA-4 antibody |
WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
KR20180027576A (en) * | 2015-07-14 | 2018-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | How to treat cancer using immune checkpoint inhibitors |
TWI765875B (en) | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | Neoantigen identification, manufacture, and use |
CN117024599A (en) * | 2016-02-05 | 2023-11-10 | 奥里尼斯生物科学私人有限公司 | Bispecific signaling agents and uses thereof |
EP3413927A4 (en) * | 2016-02-12 | 2019-11-27 | Madison Vaccines Inc. | Cancer therapy |
WO2018027524A1 (en) | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
KR20190082850A (en) | 2016-11-30 | 2019-07-10 | 어드박시스, 인크. | Immunogen compositions targeting repeated cancer mutations and methods of using the same |
RU2019138507A (en) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | ANTIBODY AGAINST LAG3 AND JOINT ANTIBODY AGAINST LAG3 AND ANTIBODY AGAINST PD-1 |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
NZ762881A (en) | 2017-09-19 | 2024-03-22 | Advaxis Inc | Compositions and methods for lyophilization of bacteria or listeria strains |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
JP2021503897A (en) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | Reduced junction epitope presentation for nascent antigens |
RU2020129827A (en) | 2018-02-13 | 2022-03-14 | Мерк Шарп И Доум Корп. | METHODS FOR THE TREATMENT OF MALIGNANT NEOPLASMS USING ANTIBODIES AGAINST PD-1 |
WO2020033283A1 (en) * | 2018-08-09 | 2020-02-13 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc |
WO2020055702A1 (en) * | 2018-09-13 | 2020-03-19 | Merck Sharp & Dohme Corp. | Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
EP3730153A1 (en) | 2019-04-26 | 2020-10-28 | Medizinische Hochschule Hannover | Personalized immunotherapy for treatment of cancer |
US20220362308A1 (en) * | 2019-09-24 | 2022-11-17 | Novome Biotechnologies, Inc. | Oral administration of genetically engineered bacteria |
CN110898012B (en) * | 2019-12-06 | 2021-08-10 | 北京大学 | Catalase-entrapped liposome connected with PD-L1 antibody and preparation method thereof |
WO2023211868A1 (en) * | 2022-04-29 | 2023-11-02 | Merck Sharp & Dohme Llc | Stable formulations of anti-ilt4 antibodies or antigen-binding fragments thererof in combination with anti-pd-1 antibodies and methods of use thereof |
WO2024026253A1 (en) * | 2022-07-25 | 2024-02-01 | Agensys, Inc. | Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab |
WO2024047585A2 (en) * | 2022-08-31 | 2024-03-07 | Proviva Therapeutics (Hong Kong) Limited | Il-15 procytokine antibody fusion proteins |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPH10510433A (en) | 1995-06-06 | 1998-10-13 | アイシス・ファーマシューティカルス・インコーポレーテッド | Oligonucleotides with high chiral purity phosphorothioate linkages |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
EP2298900A1 (en) | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
CA2404164A1 (en) | 2000-03-29 | 2001-10-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
CN109485727A (en) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody |
MX2007015942A (en) | 2005-07-01 | 2008-03-07 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1). |
DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US20110129499A1 (en) | 2008-05-19 | 2011-06-02 | Paulo Maciag | Dual delivery system for heterologous antigens |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
CN102264762B (en) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | The anti-PD 1 of people, PD L1 and PD L2 antibody and its application |
TWI686405B (en) | 2008-12-09 | 2020-03-01 | 建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Simultaneous inhibition of pd-l1/pd-l2 |
CN102469782A (en) | 2010-06-18 | 2012-05-23 | 哈洛资源公司 | Formulations and methods for solid chitosan-containing blends |
CA2829960A1 (en) * | 2011-03-11 | 2012-09-20 | John Rothman | Listeria-based adjuvants |
KR102031020B1 (en) * | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
KR102049817B1 (en) | 2011-08-01 | 2019-12-02 | 제넨테크, 인크. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
AU2012370450B2 (en) | 2012-02-21 | 2017-02-02 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
AR093984A1 (en) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN |
EP2938627B1 (en) | 2012-12-27 | 2019-03-20 | Aduro Biotech, Inc. | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
-
2015
- 2015-07-17 WO PCT/US2015/040916 patent/WO2016011357A1/en active Application Filing
- 2015-07-17 CN CN201580049879.1A patent/CN106999561A/en active Pending
- 2015-07-17 CA CA2955612A patent/CA2955612C/en active Active
- 2015-07-17 EP EP15822334.7A patent/EP3193921A4/en active Pending
- 2015-07-17 SG SG11201701149SA patent/SG11201701149SA/en unknown
- 2015-07-17 MX MX2017000857A patent/MX2017000857A/en unknown
- 2015-07-17 AU AU2015289533A patent/AU2015289533B2/en active Active
- 2015-07-17 US US14/802,607 patent/US9907849B2/en not_active Expired - Fee Related
- 2015-07-17 SG SG10201913696YA patent/SG10201913696YA/en unknown
- 2015-07-17 MA MA040344A patent/MA40344A/en unknown
- 2015-07-17 CN CN202210236053.8A patent/CN114984228A/en active Pending
- 2015-07-17 KR KR1020177004528A patent/KR20170052569A/en not_active Application Discontinuation
-
2017
- 2017-01-18 IL IL250187A patent/IL250187B/en active IP Right Grant
-
2018
- 2018-01-09 US US15/865,602 patent/US20180185483A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN106999561A (en) | 2017-08-01 |
MX2017000857A (en) | 2017-10-11 |
IL250187B (en) | 2020-10-29 |
US20160022814A1 (en) | 2016-01-28 |
CN114984228A (en) | 2022-09-02 |
MA40344A (en) | 2016-01-21 |
IL250187A0 (en) | 2017-03-30 |
US20180185483A1 (en) | 2018-07-05 |
AU2015289533B2 (en) | 2021-04-01 |
CA2955612C (en) | 2022-05-17 |
AU2015289533A1 (en) | 2017-03-02 |
SG11201701149SA (en) | 2017-04-27 |
EP3193921A1 (en) | 2017-07-26 |
EP3193921A4 (en) | 2018-04-25 |
WO2016011357A1 (en) | 2016-01-21 |
KR20170052569A (en) | 2017-05-12 |
US9907849B2 (en) | 2018-03-06 |
CA2955612A1 (en) | 2016-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250187B (en) | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer | |
HK1232153A1 (en) | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer pd-1 ido1 | |
HK1252652A1 (en) | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer | |
IL246760A0 (en) | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer | |
HK1251862A1 (en) | Methods and compositons for treating cancer | |
HK1251408A1 (en) | Methods of treating cancer | |
IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
IL254133A0 (en) | Combination of a pd-1 antagonist and eribulin for treating cancer | |
SG11201607130RA (en) | Combination method for treatment of cancer | |
WO2016154412A9 (en) | Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer | |
PT3200815T (en) | Methods and compositions for treating cancer | |
SG11201605745VA (en) | Targeting clptm1l for treatment and prevention of cancer | |
GB201408297D0 (en) | Treatment of cancer | |
GB201407837D0 (en) | Methods of cancer therapy | |
GB201417456D0 (en) | Treatment of cancer | |
GB201418640D0 (en) | Agents and methods for treatment of cancer | |
GB201414904D0 (en) | Materials and methods for treating cancer | |
GB201409362D0 (en) | Treatment of cancer | |
GB201405449D0 (en) | Treatment of cancer | |
GB201405075D0 (en) | Treatment of cancer |